Radium-223: Insight and perspectives in bone-metastatic castration-resistant prostate cancer

Federica Eleonora Buroni, Marco Giovanni Persico, Francesca Pasi, Lorenzo Lodola, Rosanna Nano, Carlo Aprile

Research output: Contribution to journalReview articlepeer-review


223Ra prolongs overall survival in symptomatic patients affected by multiple bone-metastatic castration-resistant prostatic cancer, without visceral or nodal involvement. However, many questions remain about its mechanisms of action, and its use in clinical practice is still unresolved. First of all, what is the main target of alpha-particle emission, that is, in what way does it influences the tumor microenvironment? When is the best timing in the course of the disease, extending its use to asymptomatic low-volume or even to the micrometastatic phase? What are suitable biomarkers to be employed as prognostic factors and response indicators? Which associations with other drugs and their sequence can offer the best results, and is their effect additive or synergistic? Ultimately, in the current climate of spending review, what is the optimal cost and benefit ratio regarding available treatments? In this review, we tried to answer these questions by analyzing the available scientific literature.

Original languageEnglish
Pages (from-to)5719-5730
Number of pages12
JournalAnticancer Research
Issue number11
Publication statusPublished - Nov 1 2016


  • Bone metastases
  • Castration-resistant prostatic cancer
  • Palliation of pain
  • Pharmacoeconomics
  • Radiometabolic therapy
  • Radium-223
  • Review

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Radium-223: Insight and perspectives in bone-metastatic castration-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this